Sat, Apr 19, 2014, 5:14 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Celsion Corp. Message Board

bioinvestor2013 24 posts  |  Last Activity: Mar 25, 2014 4:08 PM Member since: Jan 12, 2013
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • bioinvestor2013 by bioinvestor2013 Mar 25, 2014 4:08 PM Flag

    OXIGENE STILL UNDERVALUED '' glta

    Sentiment: Strong Buy

  • bioinvestor2013 bioinvestor2013 Feb 11, 2014 3:11 PM Flag

    your sounds like a kid at Toys are us !! you are a Clown not more !! set this guy to ignore CLOWN Buddy

  • something interesting here !! some guys only bashing here !! why they spend all his time here to bash is the real Question ?? these guys maybe LEMS patients or they are morons and have no friends to talk with other guys

    Sentiment: Strong Buy

  • bioinvestor2013 bioinvestor2013 Feb 4, 2014 9:01 AM Flag

    Oramed Pharmaceuticals PT Raised to $35.00 (ORMP) Feb 3rd, 2014 // Analysts at Aegis lifted their target price on shares of Oramed Pharmaceuticals (NASDAQ:ORMP) from $30.00 to $35.00 in a research report issued to clients and investors on Thursday, Stock Ratings Network reports. The firm currently has a “buy” rating on the stock. Aegis’ price objective would indicate a potential upside of 58.44% from the company’s current price.
    Shares of Oramed Pharmaceuticals (NASDAQ:ORMP) traded down 15.80% during mid-day trading on Thursday, hitting $18.60. The stock had a trading volume of 991,629 shares. Oramed Pharmaceuticals has a 52-week low of $5.00 and a 52-week high of $31.73. The stock’s 50-day moving average is $18.47 and its 200-day moving average is $9.73. The company’s market cap is $181.3 million.
    Other equities research analysts have also recently issued reports about the stock. Analysts at MLV Capital initiated coverage on shares of Oramed Pharmaceuticals in a research note to investors on Tuesday, January 7th. They set a “buy” rating and a $27.00 price target on the stock. Analysts at Capital Ideas Research initiated coverage on shares of Oramed Pharmaceuticals in a research note to investors on Tuesday, December 3rd. They set a “buy” rating on the stock.

    Sentiment: Buy

  • bioinvestor2013 bioinvestor2013 Feb 3, 2014 4:56 PM Flag

    Today the Bermuda Triangle works again to dump ORAMED shareholder Adam Feuerstein use The Street to Manipulate Investors Oramed is down 25% Today BY Adam Feuerstein| 02/03/14 - 09:34 AM EST **Oramed's Oral Insulin Pill Data 'Completely Worthless' *** EASY MONEY with Hedge Founds to short Stocks to make BIG MONEY ** is Adam Feuerstein a Analyst ??? really are there no other Analyst to write something about ORAMED ***

    Sentiment: Strong Buy

  • bioinvestor2013 bioinvestor2013 Feb 3, 2014 4:26 PM Flag

    Interesting how they work *** i call them ---- ( Bermuda Triangle) Hedge Founds & Jim Cramer & Adam Feuerstein *** if you pay Adam F he write everything what you want !! Jacobus paid Adam Fraudstein to write Garbage ] Lies based on really no background later he came out with ethical aspect and more more garbage !!!
    MGNT give signals this corp will not bought out at this cheap level !! $CPRX have 25 million in cash until Q1 2015 !! we have some bad manipulators here Jim Cramer every time PumP Biomarin he use Adam Feuerstein to bash about CPRX why Adam never write about Biomarin Lems patients ?? CPRX only received N American rights from Biomarin !! fact is Biomarin don`t want pay Big Money for a Takeover History don't LIE !! CPRX MgnT show with the 100 Million shelf this corp is not for free

    Sentiment: Strong Buy

  • bioinvestor2013 bioinvestor2013 Feb 3, 2014 4:01 PM Flag

    Adam Feuerstein mybe an expert of Beer and Wine and Dog research but he knows nothing about Biotech he receive his articles from John Tucker !!!

    Sentiment: Strong Buy

  • Adam Feuerstein was paid from Jacobus Pharma this is fact to write Nonsense & Lies !!! Adam Feuerstein in not a Analyst or anything else * Adam hides behind armor of being a Journalist. he is the servant of the Hedge Fund devils that play the retail investors daily ** Adam Feuerstein is absolutely a tool of the short sellers in biotech. everything he writes comes from them he scare Investors with his Lie´s with his article based on no background ** a self called analyst Adam Feuerstein He came out with a article last year from a 25 years old study from a -a family drugmaker is in "race" to get 3,4-Dap approved before $CPRX -- Jacobus study says it's only in phase II the last 25 years !! ( It won't be hard to find out why it's only in Phase II despite 25 year history !! ) only to remember nothing is for Free !! on goin Phase 2 Study's are not for Free !!! Jacobus need about 25 - 28 Million Dollar for the Phase 2 & Phase 3 Study's !! Study's from Jacobus says their compound is not safe !! this is one of the BIG reason why they are 25 year in Phase 1 b - 2 ! Jacobus received some time WARNING Letters from FDA !! FDA planed to re visit Jacobus 2014 but it BURN *** however ! * *Firdapse is a Approved drug In Europe and in sales ** Catalyst Pharmaceuticals Partners licensed the North American rights from Biomarin's drug for LEMS *** The FDA granted Firdapse for Orphan drug Status !! Firdapse is in Phase 3 *** Orphan drug status means 7 Years of exclusivity rights *** Reframing the Catalyst-Jacobus Debate Following up on the recent brushfire debate on Catalyst (Firdapse) and Jacobus (compounded amifampridine), below we highlight data points that may add valuable perspective to investors focused on the LEMS space as the contemplate the true extent of this “competition.” View from Jacobus: manufacturing in a black box. We recently scheduled a call with Jacobus Pharmaceuticals (private) in order to better understand its business model, clinical plan, regulatory strategy, compounding quality control, manufacturing capability and patient outreach. After having first scheduled a time to speak with us, on further reflection, the company’s management cancelled the call, guiding that relevant and sufficient information about Jacobus is already accessible in the public domain. Following their guidance, we redirected our attention to some of the only available sources of information on Jacobus: FDA inspection reports (Form 483) of the company’s Industrial Research Laboratory Building (Schalks Crossing Road, Plainsboro, NJ) from 2011 and 2012. The reports paint a colorful picture of the equipment, quality control, production, and storage at the Jacobus facility, where Dapsone (leprosy tx) and 4-Aminosalicylic acid USP (tuberculosis tx) are also manufactured. The following are representative observations quoted in the report: (a) “procedures designed to prevent objectionable microorganisms in drug products not required to be sterile are not established and followed”; (b) “there is failure to thoroughly investigate batches that do not meet specification”; (c) “containers used in the production of drug products are not identified at all times”; (d) “facilities used in the manufacturing and storage of components, API, and in-process materials are inadequate”; (e) “equipment used in manufacturing of drug products are not maintained in a state of repair”. The reports also containSchalks Crossing Road. Constructed by the Industrial Nuclear Reactor Laboratories, a consortium of major companies, the conical dome is 87 feet high and made of 18-inch-thick concrete clad in aluminum. It housed a laboratory for low-level atomic research (emphasis added). The reactor became obsolete and was decontaminated, and ownership reverted to the Walker-Gordon Laboratory Company. Today, it houses the offices of Walker-Gordon and the laboratories of Jacobus Pharmaceuticals. (emphasis added). At this time we are unable to ascertain if and how this could affect more stringent manufacturing quality and safety checks from a regulatory point of view, or whether FDA personnel carry and periodically employ Geiger counters during their manufacturing facility inspections at Jacobus Pharma

    Sentiment: Strong Buy

  • we expect lower Biomarin earning with more sales from Firdapse this will be very interesting for Catalyst next PPS upgrade

    Sentiment: Strong Buy

  • bioinvestor2013 bioinvestor2013 Feb 3, 2014 8:27 AM Flag

    if you pay Adam F he write everything what you want !! Jacobus paid Adam Fraudstein to write Garbage ] Lies based on really no background later he came out with ethical aspect and more more garbage !!!

  • bioinvestor2013 bioinvestor2013 Feb 2, 2014 7:37 PM Flag

    why CPRX shares down ?? read why

    @BioInvestor2013 One guy he call his self analyst Adam Feuerstein He came out with a article from a 25 years old study from a -a family drugmaker is in "race" to get 3,4-Dap approved before $CPRX -- Jacobus study says it's only in phase II the last 25 years !! ( It won't be hard to find out why it's only in Phase II despite 25 year history !! ) only to remember nothing is for Free !! on goin Phase 2 Study's are not for Free !!! Jacobus need about 25 - 28 Million Dollar for the Phase 2 & Phase 3 Study's !! jacobus Study's says their compound is not safe !! this is the one of the BIG reason why they are 25 year in Phase 1 b - 2 ! Jacobus received some time WARNING Letters from FDA !! now Jacobus Building Burn !!

    Sentiment: Strong Buy

  • bioinvestor2013 bioinvestor2013 Feb 2, 2014 7:26 PM Flag

    FDA personnel carry and periodically employ Geiger counters during their manufacturing facility inspections.

    Sentiment: Strong Buy

  • Foliage, Powder-Like Residue, Geiger Counters & Congressional Bills: Reframing the Catalyst-Jacobus Debate
    Following up on the recent brushfire debate on Catalyst (Firdapse) and Jacobus (compounded amifampridine), below we highlight data points that may add valuable perspective to investors focused on the LEMS space as the contemplate the true extent of this “competition.”
    View from Jacobus: manufacturing in a black box. We recently scheduled a call with Jacobus Pharmaceuticals (private) in order to better understand its business model, clinical plan, regulatory strategy, compounding quality control, manufacturing capability and patient outreach. After having first scheduled a time to speak with us, on further reflection, the company’s management cancelled the call, guiding that relevant and sufficient information about Jacobus is already accessible in the public domain. Following their guidance, we redirected our attention to some of the only available sources of information on Jacobus: FDA inspection reports (Form 483) of the company’s Industrial Research Laboratory Building (Schalks Crossing Road, Plainsboro, NJ) from 2011 and 2012. The reports paint a colorful picture of the equipment, quality control, production, and storage at the Jacobus facility, where Dapsone (leprosy tx) and 4-Aminosalicylic acid USP (tuberculosis tx) are also manufactured. The following are representative observations quoted in the report: (a) “procedures designed to prevent objectionable microorganisms in drug products not required to be sterile are not established and followed”; (b) “there is failure to thoroughly investigate batches that do not meet specification”; (c) “containers used in the production of drug products are not identified at all times”; (d) “facilities used in the manufacturing and storage of components, API, and in-process materials are inadequate”; (e) “equipment used in manufacturing of drug products are not maintained in a state of repair”. The reports also containSchalks Crossing Road. Constructed by the Industrial Nuclear Reactor Laboratories, a consortium of major companies, the conical dome is 87 feet high and made of 18-inch-thick concrete clad in aluminum. It housed a laboratory for low-level atomic research (emphasis added). The reactor became obsolete and was decontaminated, and ownership reverted to the Walker-Gordon Laboratory Company. Today, it houses the offices of Walker-Gordon and the laboratories of Jacobus Pharmaceuticals. (emphasis added)” See image below. At this time we are unable to ascertain if and how this could affect more stringent manufacturing quality and safety checks from a regulatory point of view, or whether FDA personnel carry and periodically employ Geiger counters during their manufacturing facility inspections.

    Sentiment: Strong Buy

  • bioinvestor2013 bioinvestor2013 Feb 2, 2014 4:12 PM Flag

    PLAINSBORO — A blaze tore through the exterior of Jacobus Pharmaceutical Saturday night. When Plainsboro police and firefighters arrived at the facility, which is in a remote location one mile off of Schalks Crossing Road, they encountered a large natural gas-fed equipment fire up against the outside of the building, with fire extending up the outside of the building, as well as a pickup truck about 20 feet away engulfed in flames, according to Plainsboro Fire Chief Jim Pedley.

    ”I called for a first alarm, which brought a total of about 20 firefighters, as well as EMS (provided by the Plainsboro Rescue Squad), the Plainsboro Township fire official and gas and electric technicians from PSE&G,” Chief Pedley said. “The gas to the building was secured and the fire was extinguished.”

    The Plainsboro Fire Company responded to the blaze at 6 p.m. and got the fire under control by 7 p.m., according to Chief Pedley.”A resident in a nearby housing development noticed what appeared to be a small brush fire in the woods behind her house and called 911,” Chief Pedley said. “Within minutes, we were alerted that the fire alarm was activated at the facility.”

    There was one injury. A firefighter slipped and fell. As a result, the firefighter went to the University Medical Center of Princeton at Plainsboro for evaluation. He has a back injury and will be undergoing additional treatment.

    The thick concrete walls of the building prevented the fire from getting inside, according to Chief Pedley.
    ”There was extensive damage to the facade of the building, but the inside of the building suffered only minor smoke damage,” Chief Pedley said.

    The cause of the fire is being investigated by the Plainsboro Township fire official.

    Responding with Plainsboro to the scene were Plainsboro Rescue Squad, Princeton Plasma Physics Lab Fire Department (Engine 66), Princeton Junction (Deputy 44 and Engine 44), Cranbury (Tower 48) and Applegarth (Rapid Intervention Team 57).

    Princeton (Engine 60) covered the Plainsboro firehouse.

  • Reply to

    shelf filing is meaningless..

    by bentam1 Feb 2, 2014 8:03 AM
    bioinvestor2013 bioinvestor2013 Feb 2, 2014 2:42 PM Flag

    Dear Stockholder:
    On September 20, 2011, the Board of Directors (the "Board") of Catalyst Pharmaceutical Partners, Inc. (the "Company") approved a Stockholder Rights Plan (the "Rights Plan"). The Rights Plan is designed to deter coercive takeover tactics, including the accumulation of shares in the open market or through private transactions and to prevent an acquiror from gaining control of the Company without offering a fair price to all of the Company’s stockholders.
    The Rights Plan is designed to ensure that our stockholders realize the long-term value of their investment in the Company and is similar to stockholder rights plans adopted by many public companies. The Rights Plan will not prevent a takeover attempt, but will encourage anyone seeking to acquire the Company to negotiate the fair value directly with the Board of Directors. The Rights Plan was not adopted in response to any current hostile takeover attempt.
    We urge you to read the enclosed "Summary of Rights to Purchase Preferred Stock," which summarizes the terms of the Rights Plan. We have also filed a Form 8-K with the U.S. Securities and Exchange Commission ("Commission") which contains a copy of the Rights Plan as adopted. The enclosed summary is qualified in its entirety by reference to the Rights Plan that we have filed with the Commission.
    Sincerely,
    Patrick J. McEnany Chairman, President and CEO October 7, 2011

    Sentiment: Strong Buy

  • Reply to

    shelf filing is meaningless..

    by bentam1 Feb 2, 2014 8:03 AM
    bioinvestor2013 bioinvestor2013 Feb 2, 2014 2:17 PM Flag

    On September 20, 2011, the Board of Directors of Catalyst Pharmaceutical Partners, Inc. approved a Stockholder Rights Plan (the ‘Rights Plan’). The Rights Plan is designed to deter coercive takeover tactics, including the accumulation of shares in the open market or through private transactions and to prevent an acquiror from gaining control of Catalyst without offering a fair price to all of Catalyst’s stockholders. For more information regarding the Rights Plan, click below. to read CPRX Homepage under Shareholder Righst Plan !!

    Sentiment: Strong Buy

  • CPP115 Orphan Drug it's more a Pipeline in a Pill / CPP115 have a fast track Appoval status !!The gigant biopharmaceutical company Pfizer (NYSE: PFE) is obtaining surprising results from its drug Lyrica. This biopharmaceutical company described in an SEC filing that Lyrica (Pregabalin) could be used to treat epilepsy, post-herpetic neuralgia, diabetic peripheral neuropathy and fibromyalgia. Lyrica is considered to have a low potential for abuse, and a limited dependence liability if misused, and is thus classified as a Schedule V drug in the U.S. Lyrica was invented by medicinal chemist Richard Bruce Silverman at Northwestern University. Silverman headed the team of scientists that discovered novel compounds of vigabatrin (CPP-115 aminotransferase inhibitors and derivatives of vi­ga­ba­trin) This compound is being developed by Catalyst Pharmaceutical Partners under the patents licensed from North­west­ern in August 2009. Pregabalin (Lyrica, Pfizer) was approved in the European Union in 2004, and received U.S. FDA approval for use in treating epilepsy, diabetic neuropathic pain, and post-herpetic neuralgia in December of that year, first appearing on the U.S. market in fall 2005. In June 2007, the FDA approved Lyrica as a treatment for fibromyalgia. It was the first drug to be approved for this indication and remained the only one until duloxetine (Cymbalta) gained FDA approval for the treatment of fibromyalgia in June 2008. Lyrica's patent will expire in March 2018 The FDA granted orphan drug designation for Firdapse™ on November 12, 2009. !! CPP-115 has received orphan drug designation in both the US and the EU for infantile spasms. In 2011 !! Orphan drugs in the U.S. are granted a seven-year period of marketing exclusivity from the date of drug approval !! CPRX has about 50 million shares fully weighted and if CPP115 and Firdpase generate the sales recently projected by the analyst at Aegis capital $2,1 billion for CPP115 and $200 million for Firdapse) that translates to gross revenues over $40 per share for CPRX. CPRX have incredible potential ! A few smart investors who bought Acadia Pharmaceuticals, Inc. (NASDAQ: ACAD) last year are jumping for joy and smiling every step of the way to the bank, while the investors who only thought about it but didn't pull the trigger, are still kicking themselves pretty hard. Surprisingly, even the most bullish Acadia enthusiasts didn't foresee shares gaining almost 1,500% in only one year making Acadia one of the best performing stocks in the entire market. Fortunately, for those who missed the boat with Acadia, there is another strikingly similar, small-cap company named Catalyst Pharmaceutical Partners, Inc. (NASDAQ: CPRX) that appears to be about one year behind Acadia and is all teed up to repeat their stunning performance. One short year ago, Acadia's market cap was less than $60 million. Today, it is $2,1 billion. Catalyst's market cap is less than $130 million. A year ago Biomarin Owns over 6,6 Million of 54 million CPRX outstanding shares !! CPP-115 is 200 times more potent than vigabatrin and pre-clinical data suggest that ! give it a R.B silverman Bonus for CPRX and you know that CPRX is clearly undervalued at this Level Biomarins $BMRN hands are on CPRX 17% ! Pfizer know R.B.Silverman well !! Actavis $ACT know CPRX CEO !! CPRX have a Big Orphan drug Pipeline BIG Pharma know this fewer than 50,000 patients suffering from Parkinson's Disease Psychosis. Catalysts CPP115 also addresses the lucrative orphan drug markets but is expected to treat more indications than Pimavanserin. CPP115 was designed by Dr. Richard Silverman, the well-known drug designer who created the blockbusters Lyrica and Neurontin for Pfizer (PFE). Catalyst Pharmaceutical partners CEO, Former was Former Chairman.from Royce Laboratories ! Royce Laboratories was acquired by Watson Pharmaceuticals 26. 12 . 1996 for about $96 Million !!Watson changed into ACTAVIS $ACT !! R.B Silverman is the Inventor of Pfizer s 4 Billion drug Lyrica ! R.B . Silverman is at CPRX go to CPRX H.P and read more ! Firdapse is Approved in Europe 2009 !! Firdapse will be Approved in US soon Firdapse is in P3 Dr. Richard Silverman, a professor of chemistry at Northwestern University, developed pregabalin, the chemical that Pfizer (PFE) now markets as Lyrica and Neurontin. A license agreement with Northwestern University, under which it acquired worldwide rights to commercialize new GABA aminotransferase inhibitors and derivatives of vigabatrin that were discovered and patented by Northwestern. Catalyst has designated the lead compound to be developed under this license as CPP-115. CPP-115 is an analogue of the existing approved vigabatrin that is being sold under the name Sabril. Sabril is currently used to treat Epilepsy and Infantile spasms. CPP-115 has two potentially significant advantages compared to CPP-109 (vigabatrin). First, CPP-115 may not cause the visual field defects associated with chronic administration of vigabatrin. Second, CPP-115 has been shown to be at least 200 times more potent than CPP-109 in both in-vitro and animal model studies. The increased potency could enable the development of superior or alternative dosage forms and routes of administration. Catalyst hopes that these important benefits will allow it to develop a broad range of other central nervous system therapies, beginning with infantile spasms, epilepsy and/or other selected diseases in which modulation of GABA levels might be beneficial, such as Tourette Syndrome, Post Traumatic Stress Disorder (PTSD) and movement disorders. CPP-115 Catalyst Pharmaceuticals is in the early development stages of developing CPP-115. CPP-115 is a drug that has the same mechanism of action as CPP-109 (an older drug in Catalyst's pipeline that is not going to be under active development unless it has positive Phase II b . CPP-109 is currently under a phase II(b) study in Tourette Syndrome, and has results expected soon , however, further back in Catalyst's pipeline, but it also has a rather large potential to have a significant impact once clinical data starts rolling in. CPP-115 offers many advantages when compared to CPP-109. The primary advantage is that Catalyst believes that CPP-115 is a more potent version of vigabitran, but with fewer side-effects. This would, if it turns out to be true, seemingly be the best of both worlds to have a drug that is more effective and with less side-effects. Currently, Catalyst is planning on developing CPP-115 in infantile spasms, for which Catalyst has orphan drug designation from the FDA. If they are ultimately successful in developing the drug for infantile spasms, it should be interesting to see how the drug is priced, considering that it would have to compete with a rather expensive drug in Questcor Pharmaceuticals' (QCOR) Acthar gel. Questcor would be one of the main competitors in this space, however, the price of Acthar gel is over $28,000 per vial. This would potentially give Catalyst some significant room to undercut Questcor in this potential market. CPP-115 may also be effective in Tourette Syndrome, and should CPP-109 be shown to be effective in Tourette Syndrome, CPP-115 would be a fantastic drug to develop in Tourette Syndrome. CPP-115 is still in the early stages of development, but it will be interesting to see what kind of a drug Catalyst has on their hands. CPP-115 also has potential in other select central nervous system indications, so the drug has a large amount of potential for shareholders than can generate the sales recently projected by the analyst at Aegis capital $2,1 billion for CPP115 and $200 million for Firdapse) that translates to gross revenues over $40 per share Catalyst Pharmaceuticals have a incredible potential CPPP-115 is 200 Times More Powerful than Sabril and it is Safer Although a derivative, CPP-115 is very different from Sabril because it is estimated to be 200 times more powerful and has also demonstrated that it does not have the same potential adverse side effect of peripheral vision loss. Because of its improved safety profile and potentially greater potency, CPP-115 is believed to have a substantially broader range of applications for indications than vigabatrin (Sabril) implying far greater sales potential. On May 22, 2012, Catalyst reported positive results from a double-blind, placebo-controlled, clinical trial evaluating the safety, tolerability and pharmacokinetic profile of CPP-115. The key findings were: CPP-115 was well tolerated at all six doses administered in the study; there were no significant adverse events, and no cardiovascular or respiratory events were reported in the study; and CPP-115 was rapidly absorbed (time to peak blood concentration was about 30 minutes). Catalyst hopes to begin further human clinical trials evaluating CPP-115 later in 2013 and intends to pursue grants from the NIH and foundations. In addition, Catalyst is seeking a strategic partner to work within the development and future commercialization of CPP-115. CPP-115 has already been granted orphan drug designation by the FDA for the treatment of infantile spasms and orphan medicinal product designation in the European Union for West's syndrome (a form of infantile spasms). Orphan drug designation has the several advantages of extended marketing exclusivity times, faster FDA approval times and substantially higher pricing than traditional drugs. Epilepsy Epilepsy affects about 2 million people in the United States and about one-third or about 650,000 are "refractory" meaning that they are resistant to treatment. CPP-115 offers the potential to treat epilepsy patients including the 650,000 refractory patients who are without treatment options and in need. Infantile Spasms "Infantile spasms" is a difficult-to-treat epilepsy syndrome that usually strikes infants between three to six months old. An estimated 8,500 infants in the US have been diagnosed with Infantile Spasms. Each year, approximately 2,500 new cases of "IS" are reported in the US and until now, no FDA-approved treatments have been available. Sabril may not be appropriate for use in all "IS" patients given the potential risk of permanent vision loss, but CPP-115 with fewer adverse effects may have a much broader appeal. New Indications for CPP-115 Catalyst is seeking to develop new prescription therapies for a wider range of other central nervous system therapies, beyond infantile spasms, epilepsy and/or other selected diseases in which modulation of GABA levels might be beneficial, such as Tourette Syndrome, Post Traumatic Stress Disorder and other movement disorders. Tourette Syndrome It is not known how many people have Tourette Syndrome but a Centers for Disease Control and Prevention study has found that 3 of every 1,000 children 6 through 17 years of age and living in the United States have been diagnosed with TS based on parent report; this represents about 148,000 children. Other studies using different methods have estimated the rate of TS at 6 per 1,000 children. Firdapse is very important to the overall long-term thesis of any investor looking to buy Catalyst Pharmaceutical's stock The market potential in simply LEMS is rather large. However, going back to the original press release announcing the acquisition of the Firdapse asset, we can find an interesting sentence which would lead investors to believe that this is only the tip of the iceberg for Firdapse: "other potential orphan central nervous system indications for Firdapse™ include Myasthenia Gravis and Congenital Myasthenic Syndrome, among others.

    Sentiment: Strong Buy

  • Reply to

    shelf filing is meaningless..

    by bentam1 Feb 2, 2014 8:03 AM
    bioinvestor2013 bioinvestor2013 Feb 2, 2014 12:28 PM Flag

    agree 100% this is a part of a Shareholder protection plan !! MGNT give signals this corp will not bought out at this cheap level !! $CPRX have 25 million in cash until Q1 2015 !! we have some bad manipulators here Jim Cramer every time PumP Biomarin he use Adam Feuerstein to bash about CPRX why Adam never write about Biomarin Lems patients ?? CPRX only received N American rights from Biomarin !! fact is Biomarin don`t want pay Big Money for a Takeover History don't LIE !! CPRX MgNT show with the 100 Million shelf this corp is not for free !! read my blog !! am online Twitter !!

    Sentiment: Strong Buy

  • bioinvestor2013 bioinvestor2013 Jan 29, 2014 5:04 PM Flag

    IsoRay test new 52 high in the next weeks !! GLTA

    Sentiment: Strong Buy

  • bioinvestor2013 bioinvestor2013 Jan 23, 2014 9:58 PM Flag

    every Board need a CLOWN like Biowreck

CLSN
3.27+0.14(+4.47%)Apr 17 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Rayonier Inc.
NYSEThu, Apr 17, 2014 4:03 PM EDT